Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

STRATA Skin Sciences (SSKN) Cash from Financing Activities (2016 - 2025)

STRATA Skin Sciences (SSKN) has disclosed Cash from Financing Activities for 13 consecutive years, with $1.4 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities changed N/A to $1.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.6 million through Dec 2025, up 85.92% year-over-year, with the annual reading at $3.6 million for FY2025, 85.92% up from the prior year.
  • Cash from Financing Activities hit $1.4 million in Q4 2025 for STRATA Skin Sciences, down from $2.2 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $7.0 million in Q2 2023 to a low of -$500000.0 in Q4 2022.
  • Historically, Cash from Financing Activities has averaged $1.5 million across 5 years, with a median of $739500.0 in 2021.
  • Biggest five-year swings in Cash from Financing Activities: surged 1968.27% in 2024 and later rose 12.82% in 2025.
  • Year by year, Cash from Financing Activities stood at $92000.0 in 2021, then crashed by 643.48% to -$500000.0 in 2022, then surged by 79.2% to -$104000.0 in 2023, then soared by 1968.27% to $1.9 million in 2024, then dropped by 28.62% to $1.4 million in 2025.
  • Business Quant data shows Cash from Financing Activities for SSKN at $1.4 million in Q4 2025, $2.2 million in Q3 2025, and $1.9 million in Q3 2024.